In a phase 2 trial of 421 healthy Philippine infants, three dose-ranging formulations of 25-valent IVT-PCV25 had acceptable safety versus Prevnar-20; IgG exceeded 0.35 μg/mL for 19/25 serotypes, with no clear dose effect.
RCTn = 421
Bravo et al. Phase 2 trial to evaluate the safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine (IVT-PCV25) in infants